Essential thrombocythemia
Therapeutic area
Hematology
Rare disease
Yes
- Definition
- A chronic myeloproliferative neoplasm that involves primarily the megakaryocytic lineage. It is characterized by sustained thrombocytosis in the blood, increased numbers of large, mature megakaryocytes in the bone marrow, and episodes of thrombosis and/or hemorrhage. (WHO, 2008)
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- Yes
- Listing at source
- Listed
- Condition name
- Essential thrombocythemia
- Therapeutic area
- Hematology
- essential thrombocythemia
- ET
- essential thrombocytemia
- essential thrombocythemia
- essential thrombocytosis
- primary thrombocythemia
- primary thrombocytosis
- idiopathic thrombocythemia
- Severity
- Moderate
- Hematology
- Immunology
- Oncology
- Rheumatology
- MONDO ID
- MONDO:0005029
- Parent condition
- MONDO:0002249
Related records
Broader conditions (29)
- Blood platelet disease
- Bone cancer
- Bone disorder
- Bone marrow cancer
- Bone marrow disorder
- Bone marrow neoplasm
- Bone neoplasm
- Cancer
- Cancer or benign tumor
- Connective tissue disorder
- Connective tissue neoplasm
- Disease
- Disease by body system or component
- Disease by etiologic mechanism
- Hematologic disorder
- Hematopoietic and lymphoid cell neoplasm
- Hematopoietic and lymphoid system neoplasm
- Human disease
- Immune system cancer
- Immune system disorder
Trials (228)
- 12-O-Tetradecanoylphorbol-13-acetate in Treating Patients With Hematologic Cancer or Bone Marrow Disorder
- 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Systemic Mastocytosis
- 18F-FLT (PET/CT) in Pediatrics With Myeloproliferative Neoplasms
- 18F-FLT (PET/CT) in Prefibrotic/Early Primary Myelofibrosis and Essential Thrombocythemia
- 3-AP and Fludarabine in Treating Patients With Myeloproliferative Disorders, Chronic Myelomonocytic Leukemia, or Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia
- 3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer
- 506U78 in Treating Patients With Hematologic Cancer and Kidney or Liver Impairment
- A Phase 1/2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Hematologic and Myeloproliferative Malignancies
- A Phase 1/2 Study of Oral SB1518 in Subjects With Chronic Idiopathic Myelofibrosis
- A Phase 2 Study to Assess STP938 (Dencatistat) as a Monotherapy in Adults With High Risk Essential Thrombocythaemia - The VECTRA Trial
- A Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants With Essential Thrombocythemia
- A Phase Ib/II Dose-finding Study to Assess the Safety and Efficacy of LDE225 + INC424 in Patients With MF
- A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)
- A Safety Study of XL019 in Adults With Myelofibrosis
- A Single-arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of P1101 in Adults With ET
- A Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm
- A Study in Myeloproliferative Disorders
- A Study of Anagrelide and Hydroxyurea in High-Risk Essential Thrombocythemia Patients
- A Study of Anagrelide Controlled Release (GALE-401) in Patients With High Platelet Counts Due to Bone Marrow Disorders
- A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)
Approved drugs (2)
- Anagrelide hydrochloride
- Momelotinib dihydrochloride
Drugs in development (30)
- Acetylcysteine Phase 1
- Anagrelide Phase 3
- Arsenic trioxide Phase 1
- Ascorbic acid Phase 1
- Aspirin Phase 3
- AZD-1480 Phase 1
- Bomedemstat Phase 3
- Busulfan Phase 3
- Cytarabine Phase 1
- Daunorubicin Phase 1
- Givinostat Phase 2
- Hiltonol Phase 1
- Hydroxyurea Phase 3
- Idasanutlin Phase 1
- Imetelstat Phase 2
- Interferon alfa Phase 3
- Lenalidomide Phase 2
- Lestaurtinib Phase 2
- Momelotinib Phase 2
- Navtemadlin Phase 2